A small prospective case series reports that Gallium-68–labeled fibroblast activation protein inhibitor PET-CT can detect ongoing, actively remodeling myocardial fibrosis in Anderson–Fabry disease—beyond what standard late gadolinium enhancement reflects. The study, published in EJNMMI Reports, evaluated three genetically confirmed patients under clinical trial NCT07351136. Investigators integrated PET measurements with conventional multimodal cardiology workups, including 12-lead ECG, echocardiography, and cardiovascular magnetic resonance with native T1 mapping and late gadolinium enhancement, alongside circulating biomarker profiling. The imaging approach targets active fibrogenesis through activated fibroblasts rather than established scar tissue. If validated in larger cohorts, the platform could improve patient stratification and treatment monitoring in lysosomal storage cardiomyopathy, where fibrosis biology evolves over time.